18^th World Drug Delivery Summit

About Conference

Welcome to the 18th World Drug Delivery Summit , scheduled to take place on September 19-20, 2025, in Paris, France. This premier event will bring together leading researchers, scientists, healthcare professionals, and industry pioneers from around the globe to explore the latest advancements in drug delivery systems.

Themed "Smart Drug Delivery Systems: Innovations in Controlled Release", this summit aims to showcase groundbreaking research and cutting-edge technologies that are transforming the field of drug delivery. From intelligent materials and stimuli-responsive systems to precision-targeted therapies, the conference will provide a platform to discuss novel approaches that enhance therapeutic efficacy and patient outcomes.

Drug Delivery 2025 offers an excellent opportunity for participants to engage in insightful discussions, share their expertise, and collaborate on solutions to current challenges. The program will feature keynote presentations, interactive workshops, and networking sessions designed to foster meaningful connections and inspire innovation.

Join us in Paris for this exceptional event as we explore the future of drug delivery and its potential to revolutionize healthcare. We look forward to welcoming you to an unforgettable experience at Drug Delivery 2025!

Sessions and Tracks

Track 01: Recent Advances and Innovations in Drug Delivery

The convergence of materials science, nanotechnology, biotechnology, and engineering has fueled the development of novel drug delivery systems, enabling improved efficacy, reduced toxicity, and enhanced patient adherence. Controlled and sustained-release delivery systems represent another major stride in modern pharmaceutical design. Using biodegradable polymers such as polylactic-co-glycolic acid, scientists can formulate injectable depots, implants, and microspheres that slowly release drugs over a defined period. These systems are invaluable in treating chronic diseases such as diabetes, schizophrenia, and cancer, where frequent dosing is inconvenient or impractical. Smart or responsive drug delivery systems are also gaining widespread attention. These systems are designed to release their contents only in response to specific physiological or environmental stimuli such as pH changes, enzymes, temperature, or magnetic fields. Artificial intelligence and machine learning are beginning to play a role in the design and optimization of drug delivery systems. These technologies can analyze large datasets to predict drug-excipient compatibility, optimize release kinetics, and support regulatory documentation. They can also help in modeling patient-specific responses, paving the way for precision drug delivery strategies.

Key topics include:

• Novel nanocarrier systems for targeted delivery
• Smart polymers and stimuli-responsive systems
• Advances in mRNA and gene delivery platforms
• AI and computational modeling in formulation science
• Clinical translation and regulatory considerations

Track 02: Targeted Drug Delivery Technologies

Targeted drug delivery technologies represent a significant advancement in the field of pharmaceutical sciences. Unlike traditional delivery methods that distribute drugs systemically throughout the body, targeted systems are designed to direct therapeutic agents precisely to the site of action, minimizing exposure to healthy tissues. This approach enhances treatment efficacy, reduces adverse effects, and allows for lower overall dosages of potent drugs. The concept of targeting in drug delivery is based on the ability to identify specific biomarkers, receptors, or physiological conditions that are unique to diseased tissues, such as cancer cells or sites of inflammation. There are two primary strategies in targeted drug delivery: passive targeting and active targeting. Passive targeting relies on the natural physiology of certain diseases. Active targeting, on the other hand, involves functionalizing the drug carrier with ligands such as antibodies, peptides, or small molecules that can bind selectively to receptors overexpressed on the surface of diseased cells.

Key Topics:

• Principles of passive and active targeting
• Ligand-receptor interactions in targeted therapy
• Antibody-drug conjugates and their applications
• Nanoparticle-based systems for tumor targeting
• Stimuli-responsive and environment-sensitive carriers
• Strategies for crossing the blood-brain barrier
• Cell-based and exosome-mediated drug delivery
• Personalized targeted therapies in cancer and neurology
• Challenges in clinical translation and regulatory compliance

Track 03: Nanotechnology in Drug Delivery

Nanotechnology has emerged as one of the most promising and transformative fields in drug delivery, offering innovative solutions to overcome the limitations of conventional pharmaceutical formulations. By manipulating materials at the nanometer scale, researchers can design delivery systems that improve the solubility, stability, bioavailability, and therapeutic index of drugs. Nanotechnology not only enables targeted and controlled release but also provides strategies for delivering complex molecules such as proteins, peptides, and nucleic acids. Nanoparticles are defined as particles ranging in size from 1 to 1000 nanometers. Their small size allows them to penetrate biological barriers, circulate longer in the bloodstream, and accumulate at the site of disease, especially in cancerous tissues. There are several types of nanocarriers used in drug delivery. Liposomes are spherical vesicles composed of lipid bilayers, capable of encapsulating both hydrophilic and hydrophobic drugs. Dendrimers are highly branched, tree-like polymers that can be functionalized with drugs, targeting ligands, or imaging agents. 

Key Topics:

• Types of nanocarriers: liposomes, dendrimers, polymeric nanoparticles, and lipid-based systems
• Nanoparticle fabrication techniques and scalability
• Surface modification and ligand-mediated targeting
• Stimuli-responsive and smart nanocarriers
• Nanotechnology in gene and mRNA delivery
• Nanomedicine for cancer, infectious diseases, and neurological disorders
• Regulatory challenges and safety concerns in nanomedicine
• Theranostics: integrating imaging and therapy
• Personalized nanomedicine approaches

Track 04: Transdermal and Topical Therapies

Transdermal and topical drug delivery systems have emerged as effective alternatives to traditional routes of drug administration. These non-invasive approaches enable direct delivery of therapeutic agents through the skin, offering several advantages including avoidance of gastrointestinal degradation, bypassing first-pass metabolism in the liver, and improved patient compliance. These systems are particularly beneficial for chronic conditions, localized disorders, and patients who have difficulty swallowing oral medications. Transdermal delivery refers to the systemic administration of drugs through the skin, where the drug is absorbed into the bloodstream after crossing various skin layers. Microneedle patches have shown promise for delivering not only small molecules but also biologics, including insulin, peptides, and vaccines. These patches are easy to apply, cause minimal discomfort, and can be self-administered, making them particularly valuable in public health initiatives and remote settings. Topical therapies are designed for local action and are widely used in dermatology, pain relief, and antimicrobial treatments. Creams, ointments, gels, and lotions are commonly used dosage forms. Thermoresponsive and pH-sensitive hydrogels are being developed to optimize drug delivery through the skin, especially in wound care. 

Key Topics:

• Mechanisms and principles of transdermal and topical delivery
• Medicated patches for systemic drug administration
• Microneedle technology and minimally invasive systems
• Enhancers: chemical, iontophoresis, and sonophoresis
• Topical formulations: creams, gels, and ointments
• Nanocarriers for skin penetration and controlled release
• Hydrogel-based systems for wound care and inflammation
• Vaccine delivery through microneedle patches
• Clinical applications and patient compliance
• Challenges in skin permeability, irritation, and scalability

Track 05: Oral Drug Delivery Strategies

Oral drug delivery remains the most preferred and widely used route of administration across the globe, primarily due to its convenience, non-invasiveness, and ease of self-administration. Controlled release and sustained release formulations have significantly transformed oral drug therapy by enabling the gradual release of a drug over an extended period. Matrix tablets, osmotic pump systems, and coated granules are commonly used to achieve a controlled drug release profile. Gastro-retentive drug delivery systems are another important innovation. These systems are designed to remain in the stomach for prolonged periods, increasing the bioavailability of drugs that are primarily absorbed in the upper gastrointestinal tract or are unstable in the intestinal environment. Floating tablets, bioadhesive systems, and expandable formulations are examples of technologies used to achieve gastric retention. Mucoadhesive tablets and films enhance the residence time of drugs in the oral cavity or gastrointestinal tract by adhering to mucosal surfaces. For pediatric and geriatric populations, where swallowing large tablets may be challenging, orally disintegrating tablets and fast-melting films offer an effective alternative. Enteric coatings are commonly used to protect drugs from the acidic environment of the stomach. Artificial intelligence and computational modeling are being integrated into formulation development to predict dissolution behavior, optimize excipient combinations, and design release kinetics tailored to specific patient profiles.

Key Topics:

• Solubility enhancement techniques for poorly soluble drugs
• Controlled and sustained release oral formulations
• Gastro-retentive and mucoadhesive systems
• Fast-dissolving tablets and oral films
• Nanotechnology applications in oral delivery
• Oral delivery of peptides, proteins, and nucleic acids
• Enteric coatings and site-specific release strategies
• Computational modeling and artificial intelligence in formulation design
• Patient-centric design for pediatric and geriatric populations
• Regulatory considerations and manufacturing challenges

Track 06: Injectable and Implantable Drug Systems

Injectable and implantable drug delivery systems play a vital role in modern therapeutics, especially in situations that demand rapid onset of action, localized treatment, long-term sustained release, or the administration of biologically sensitive molecules such as proteins and peptides. These systems provide targeted delivery, prolonged drug action, and improved patient compliance for a variety of acute and chronic conditions including cancer, diabetes, central nervous system disorders, and infections. Biodegradable polymer-based injectables have become a cornerstone in sustained-release drug delivery. Polymers such as polylactic-co-glycolic acid are used to form microparticles or in situ forming depots. Implantable drug delivery systems offer long-term, localized, and controlled drug release. Biocompatibility, sterility, and patient safety are critical factors in the development of injectable and implantable systems. These formulations and devices must undergo extensive biocompatibility testing and quality control to ensure safety during long-term use. Scalability and cost-effectiveness are also important considerations, especially when moving from laboratory development to commercial manufacturing. 

Key Topics:

• Types and routes of injectable drug delivery
• Long-acting depot injections and biodegradable polymers
• Liposomes, nanoparticles, and micelles for injectables
• In situ forming gels and injectable implants
• Design and application of subdermal and intracavitary implants
• Ocular implants and site-specific delivery devices
• Smart implants and controlled-release microchips
• Biocompatibility, sterilization, and safety concerns
• Applications in oncology, contraception, CNS disorders, and ophthalmology
• Manufacturing, scalability, and regulatory perspectives

Track 07: Bioprinting Technologies in Pharmaceuticals

Bioprinting is transforming the landscape of pharmaceutical sciences by enabling the fabrication of complex, tissue-like structures using 3D printing techniques. This innovative technology uses living cells, biomaterials, and bioactive molecules as “bio-inks” to print customized biological constructs layer-by-layer, mimicking the architecture and function of natural tissues. In the pharmaceutical industry, bioprinting holds immense promise for drug testing, disease modeling, personalized medicine, and future therapeutic delivery. Bioprinting also plays a key role in personalized medicine. Cells derived from individual patients can be used to create personalized tissue models. This allows researchers to test how a specific patient might respond to various drugs before selecting the most effective treatment. It also opens the door for the development of patient-specific implants or drug delivery devices. As research progresses, the integration of artificial intelligence, robotics, and 4D bioprinting is further expanding the capabilities of this technology. The future may include bioprinted organs for transplantation and customizable drug delivery systems tailored to individual patients. 

Key topics:

• Types of bioprinting techniques and bio-inks
• Bioprinted tissue models for drug screening
• Personalized drug response testing
• Bioprinted implants for drug delivery
• Ethical and regulatory considerations
• Integration with AI and data modeling
• Limitations and future directions

Track 08: Gene Editing Tools for Therapy

Gene editing is a breakthrough technology that enables precise changes to DNA in living cells. Tools such as CRISPR-Cas9, TALENs, and zinc finger nucleases allow researchers to correct genetic mutations, disrupt harmful genes, or insert beneficial genes for therapeutic purposes. These advances are shaping the future of personalized and regenerative medicine. Gene editing also holds potential in cancer therapy. By modifying immune cells to target specific cancer markers, treatments like CAR-T cells have demonstrated strong effects against certain blood cancers. In infectious diseases, gene editing is being explored to combat viruses like HIV. The goal is to disrupt viral DNA integrated into host cells, offering a path toward eradicating infections rather than merely controlling them. Current strategies include viral vectors, lipid nanoparticles, and electroporation. Each method has strengths and limitations related to efficiency, safety, and tissue targeting. Improving these delivery systems remains a key area of research.

Key topics:

• Gene editing platforms and mechanisms
• Therapeutic applications in genetic diseases
• Advances in cancer immunotherapy
• Delivery technologies and limitations
• Off-target effects and safety monitoring
• Ethical and regulatory frameworks
• Prospects for in vivo gene editing

Track 09: Regulatory Innovation for Drug Approvals

As pharmaceutical technologies advance rapidly, regulatory systems must evolve to keep pace. Regulatory innovation aims to develop flexible, science-based processes that ensure safety while accelerating access to life-saving therapies. This is especially important for novel treatments such as gene therapy, mRNA vaccines, and cell-based products. Agencies such as the US Food and Drug Administration and the European Medicines Agency have introduced fast-track and breakthrough therapy designations. These programs allow for earlier interactions with developers, rolling submissions, and conditional approvals based on surrogate endpoints. These tools are helping bring critical treatments to patients faster without compromising standards. Artificial intelligence is also contributing to regulatory modernization. AI tools are used to analyze trial data, monitor drug safety signals, and detect manufacturing issues in real time. Regulatory authorities are working to build internal expertise and develop guidance for the use of digital tools in product evaluation. Global harmonization is another focus area. Cross-border collaboration helps standardize requirements, reduce duplication, and promote efficient drug development. Programs like the International Council for Harmonisation aim to align technical standards and streamline regulatory review across regions.

Key topics:

• Accelerated pathways for high-impact drugs
• Role of real-world evidence in approvals
• Artificial intelligence in regulatory review
• Modern clinical trial designs
• Oversight of novel therapies
• Digital health integration and data privacy
• International cooperation and harmonization

Track 10: Artificial Intelligence in Drug Formulation

Artificial intelligence is revolutionizing the pharmaceutical industry by accelerating the development and optimization of drug formulations. Traditionally, drug formulation has relied heavily on trial-and-error approaches, involving extensive experimentation and time-consuming processes. With the integration of AI-driven technologies, scientists and pharmaceutical companies can now predict optimal drug compositions, stability, solubility, and delivery profiles more efficiently and accurately. AI also plays a critical role in improving drug solubility and stability. Many new chemical entities have poor aqueous solubility, making formulation a major challenge. Artificial Intelligence models can suggest excipients, surfactants, or nanoparticle strategies that enhance solubility based on prior data patterns. Similarly, predictive tools can assess degradation pathways and suggest stabilizers or packaging solutions. Formulation of controlled-release systems also benefits from AI. Algorithms can simulate release profiles under various physiological conditions, allowing formulators to fine-tune polymer matrices or coating materials. This is particularly useful for developing long-acting injectables, transdermal patches, and oral sustained-release systems.

Key topics:

• Predictive modeling for formulation design
• AI in solubility and stability enhancement
• Optimization of controlled-release systems
• Personalized formulation strategies using AI
• Robotics and AI in high-throughput screening
• AI tools for quality and compliance
• Challenges and future directions in AI adoption

Track 11: Green Nanotechnology for Drug Development

Green nanotechnology represents the convergence of nanoscience with environmentally sustainable practices in the pharmaceutical industry. As concerns grow over ecological impact, toxicity, and resource sustainability, green nanotechnology aims to design drug delivery systems that are safe, biodegradable, efficient, and eco-friendly throughout their lifecycle from synthesis to disposal. Traditional methods for creating nanocarriers often involve toxic solvents, harsh chemicals, high energy consumption, and non-biodegradable materials. Green nanotechnology addresses these concerns by emphasizing clean synthesis methods, renewable materials, and minimal environmental waste. This aligns with the broader goals of green chemistry, which seeks to eliminate hazardous substances and reduce the environmental footprint of scientific innovation. Lipid-based nanoparticles, such as solid lipid nanoparticles and nanostructured lipid carriers, are also considered part of green nanotechnology when prepared using non-toxic lipids and surfactants. Toxicological safety is a key advantage. Many green-synthesized nanoparticles show reduced cytotoxicity and genotoxicity, making them more suitable for sensitive applications such as pediatric medicine, dermatology, and ophthalmology. 

Key topics:

• Biosynthesis of nanoparticles using plants and microbes
• Biopolymer-based nanocarriers for drug delivery
• Green synthesis of metal nanoparticles
• Eco-friendly materials in nanomedicine
• Lipid-based green nanoparticle systems
• Applications in cancer, infections, and chronic diseases
• Biodegradability and recyclability of nanocarriers
• Safety, regulation, and scale-up challenges

Track 12: Quantum Computing in Drug Discovery

Quantum computing is emerging as a disruptive technology in the pharmaceutical industry, with the potential to revolutionize drug discovery and development. The integration of quantum computing into pharmaceutical workflows will require collaboration among quantum physicists, chemists, data scientists, and regulatory authorities. Education, infrastructure development, and ethical guidelines will be essential to ensure safe and effective use of quantum-derived insights. Quantum computing also enhances the lead optimization phase. During this stage, potential drug molecules to improve their potency, selectivity, and pharmacokinetic properties. Quantum algorithms can simulate reaction pathways, binding energies, and molecular conformations faster than classical methods, enabling more informed decisions about which compounds to pursue further. Quantum chemistry is another area where quantum computing excels. Quantum computing represents a major leap forward in computational drug discovery. Its ability to handle complex biological problems, accelerate timelines, and improve the precision of therapeutics may significantly reduce the cost and failure rate of drug development, ultimately benefiting patients and healthcare systems worldwide. 

Key topics:

• Introduction to quantum computing and qubits
• Applications in molecular and quantum chemistry
• Use in protein modeling and drug design
• Quantum machine learning for biological data
• Role in personalized medicine and precision therapies
• Drug formulation and physicochemical modeling
• Current limitations and future advancements
• Integration strategies for pharmaceutical industries

Track 13: Advanced Excipients in Drug Formulation

Excipients, once considered inactive components of pharmaceutical products, are now playing a crucial role in advancing drug delivery and formulation science. Modern drug development increasingly relies on innovative and multifunctional excipients to enhance solubility, stability, bioavailability, and targeted delivery of active pharmaceutical ingredients. With the growing number of complex molecules such as poorly soluble drugs, biologics, and personalized medicines, the demand for advanced excipient technologies has become more important than ever. Functional excipients are also being used to control the release profile of drugs. Matrix-forming polymers, pH-sensitive coatings, and swelling agents allow for the design of extended-release, delayed-release, or pulsatile formulations. These systems help maintain therapeutic drug levels over longer periods, reduce dosing frequency, and improve patient compliance. Nanotechnology has also led to the development of nano-excipients such as dendrimers, nanosilica, and nanocrystalline cellulose. Smart excipients responsive to external stimuli such as temperature, pH, light, or enzymes are being integrated into advanced formulations. These intelligent systems release the drug only under specific physiological conditions, allowing for site-specific targeting in cancer therapy, gastrointestinal disorders, or inflammatory diseases. Regulatory authorities are also recognizing the critical role of excipients in ensuring drug product quality and performance.Advanced excipients are no longer passive ingredients but active enablers of innovative drug delivery. 

Key topics:

• Solubility enhancement through cyclodextrins and polymers
• Controlled release using matrix and coating agents
• Stabilizing excipients in biologic formulations
• Lipid-based and nano-formulation excipients
• Smart excipients responsive to stimuli
• Regulatory challenges and safety assessment
• Role in personalized and 3D printed formulations
• Sustainable and green excipient development

Track 14: Bioelectronics in Precision Drug Delivery

Bioelectronics is a rapidly emerging field that bridges biology and electronics to create smart, implantable, or wearable systems capable of interacting with biological processes in real time. In the context of drug delivery, bioelectronic devices enable highly precise, programmable, and responsive therapies that go far beyond conventional dosing strategies. By using electrical signals to control drug release, stimulate tissues, or monitor physiological parameters, these systems represent the next frontier in personalized and adaptive medicine. Bioelectronic drug delivery systems typically involve miniature, implantable devices that can store and release medication on-demand. These devices are often controlled wirelessly and can be programmed to release specific doses at precise times or in response to physiological triggers such as changes in pH, temperature, glucose levels, or neural activity. This makes them ideal for managing chronic conditions where fluctuating symptoms require highly tailored treatment. Wearable bioelectronic patches are also being developed for transdermal drug delivery. These patches use microcurrents or iontophoresis to enhance skin permeability and facilitate deeper penetration of drugs, improving the efficacy of topical therapies. Such systems are being studied for the delivery of drugs in dermatology, pain relief, hormone therapy, and even chemotherapy. Bioelectronic delivery systems are particularly promising in oncology, where localized treatment is crucial to minimize systemic toxicity. Bioelectronics embodies the future of precision medicine, where real-time data, adaptive systems, and personalized treatment plans converge to deliver safer and more effective therapies tailored to the unique needs of each patient.

Key topics:

• Implantable bioelectronic drug delivery systems
• Closed-loop therapy guided by biosensors
• Neurostimulation combined with drug reservoirs
• Smart transdermal patches and microcurrent delivery
• Electro-responsive materials in formulations
• Applications in chronic disease and oncology
• Biocompatibility, miniaturization, and power challenges
• Regulatory and manufacturing considerations 

Track 15: Major Challenges in Drug Delivery

The field of drug delivery continues to evolve rapidly, yet it faces several enduring and emerging challenges that impact the safety, effectiveness, scalability, and patient acceptability of pharmaceutical treatments. These challenges are not limited to scientific and technological aspects alone but also encompass biological, regulatory, and economic dimensions. Understanding and addressing these issues is essential for optimizing therapeutic outcomes and facilitating the successful translation of new therapies from the laboratory to clinical use. Targeted delivery of drugs to specific tissues or cells is another major obstacle. While site-specific delivery is desirable to enhance efficacy and minimize side effects, achieving it requires highly sophisticated systems. This includes the development of carriers that can navigate biological barriers, avoid premature degradation, and bind selectively to target receptors. Biological barriers such as the blood-brain barrier, gastrointestinal mucosa, and cellular membranes limit the penetration and distribution of therapeutic agents. The blood-brain barrier, for example, restricts the passage of most drugs into the central nervous system, creating difficulties in treating neurological disorders. Patient adherence to treatment regimens is often compromised by complex administration protocols, painful delivery methods, or frequent dosing. This is particularly problematic in chronic conditions such as diabetes, cancer, and psychiatric disorders. Immunogenicity and toxicity of delivery systems, especially newer platforms like nanoparticles, liposomes, and viral vectors, pose significant risks. 

Key topics:

• Low solubility and poor bioavailability
• Limitations in tissue targeting and specificity
• Barriers such as the blood-brain and mucosal membranes
• Instability of biologics and sensitive molecules
• Patient non-adherence and delivery discomfort
• Immunogenicity and long-term toxicity
• Manufacturing complexity and scalability issues
• Regulatory ambiguity for advanced delivery platforms
• Integration of multidisciplinary solution

Track 16: Peptide and Protein Drug Delivery

Peptide and protein therapeutics have become essential tools in modern medicine, offering high specificity, potent biological activity, and the ability to target previously undruggable pathways. Used in areas such as oncology, endocrinology, immunology, and rare diseases, these macromolecules present significant therapeutic advantages over traditional small-molecule drugs. However, their delivery remains one of the most challenging aspects of pharmaceutical development due to their inherent instability, large molecular size, and poor membrane permeability. Nasal and pulmonary routes provide attractive alternatives for non-invasive systemic delivery. The nasal cavity and lungs offer a large surface area, rich blood supply, and bypass first-pass metabolism. Intranasal sprays and dry powder inhalers have been studied for peptides like oxytocin, glucagon, and insulin. These methods allow for rapid absorption and are useful for both acute and chronic applications. Transdermal drug delivery is another area of focus. While the skin presents a significant barrier to large molecules, technologies like microneedle patches and iontophoresis have been developed to enhance transdermal absorption. Chemical modification techniques such as PEGylation and lipid conjugation are commonly used to enhance the pharmacokinetics of peptides and proteins. 

Key topics:

• Enzymatic degradation and protective strategies
• Oral, nasal, pulmonary, and transdermal delivery methods
• Microneedles and sustained-release systems
• Nanocarriers and lipid-based formulations
• PEGylation and chemical modifications
• Receptor-mediated transport mechanisms
• Immunogenicity, stability, and cold chain logistics
• Clinical translation and regulatory challenges

Track 17: Business Opportunities in Drug Delivery

The global drug delivery market is rapidly expanding, driven by increasing demand for more effective, targeted, and patient-friendly therapies. Advances in nanotechnology, biologics, biosensors, and personalized medicine have created a fertile environment for innovation, attracting pharmaceutical companies, biotech firms, contract research organizations, medical device manufacturers, and digital health startups. As healthcare systems shift toward precision, efficiency, and improved patient compliance, drug delivery is no longer just a scientific endeavor it is a strategic business frontier. Biologics and biosimilars continue to dominate the pharmaceutical pipeline, creating demand for specialized delivery solutions that support stability, precision dosing, and patient self-administration. Licensing and technology transfer models offer pathways for academic institutions, startups, and research organizations to monetize innovative drug delivery technologies. Personalized medicine is also driving a shift in delivery strategies. Tailored drug formulations, adaptive dosing, and combination therapy systems are becoming viable through digital platforms, flexible manufacturing, and real-time diagnostic data. The future of drug delivery lies not only in medical breakthroughs but in scalable, investable solutions that bridge science, technology, and business. Companies that integrate advanced formulation design with commercial foresight, digital tools, and patient-centered approaches will be leaders in the evolving therapeutic market. 

Key topics:

• New routes of administration and delivery devices
• Delivery solutions for biologics and complex molecules
• Integration of sensors and connected health technologies
• Growth of outsourcing and development partnerships
• Licensing, startups, and innovation pipelines
• Personalized and precision delivery models
• Affordable solutions for global health access
• Investment trends, mergers, and commercial scaling

Track 18: Long acting injectables and depot systems

Long acting injectable formulations and depot drug delivery systems are transforming how medications are administered for chronic and long term conditions. These systems gradually release the active drug over extended periods, reducing dosing frequency and improving patient adherence. They are especially useful in managing psychiatric disorders, hormonal therapies, metabolic diseases, and infectious diseases where maintaining steady drug levels is crucial. These delivery systems often use biodegradable polymers like poly lactic-co-glycolic acid, which degrade over time to release the drug in a controlled manner. Other formats include oil-based suspensions, liposomal carriers, and solid implants, each designed to provide sustained action for durations ranging from weeks to several months. Applications of long acting systems are widespread. In psychiatry, they help stabilize patients with schizophrenia and bipolar disorder by eliminating the need for daily medication. In endocrinology, depot formulations of insulin or GLP-1 agonists offer improved glucose control. Oncology treatments are using sustained release systems to maintain therapeutic levels of chemotherapy while reducing systemic toxicity. 

Key topics:

• Biodegradable materials and release control
• Injectable and implantable delivery systems
• Use in psychiatry, oncology, and hormone therapies
• Formulation challenges and patient safety
• Ultra long acting designs under development
• Applications in global and preventive healthcare

Track 19: Ocular Drug Delivery

Ocular drug delivery presents unique challenges due to the complex anatomy and physiology of the eye, including barriers such as the corneal epithelium, blood-retinal barrier, and nasolacrimal drainage system. Traditional methods such as eye drops and ointments often result in poor bioavailability, as less than 5% of the administered dose may reach intraocular tissues. Therefore, advanced drug delivery systems are being developed to enhance therapeutic efficacy and patient compliance. Current strategies for ocular drug delivery focus on both anterior and posterior segment diseases like conjunctivitis, glaucoma, uveitis, diabetic retinopathy, and age-related macular degeneration. Technologies such as in situ gelling systems, nanoparticles, microneedles, liposomes, and implants have emerged as promising tools. For instance, nanocarriers like dendrimers and lipid-based systems can bypass the corneal barrier and provide sustained release. Intravitreal injections are widely used for posterior segment diseases, but their invasiveness has led to the development of less invasive alternatives such as subconjunctival and transscleral routes. Drug-eluting contact lenses and ocular inserts also offer innovative platforms that ensure sustained drug release without disturbing vision. 

Key topics:

• Barriers to effective ocular drug delivery
• Nanocarrier-based delivery systems
• Implants and ocular inserts
• Drug-eluting contact lenses
• Targeted therapies for anterior and posterior segment diseases
• Regulatory challenges in ocular therapeutics

Track 20: Nucleic Acid-based Drug Delivery

Nucleic acid-based drug delivery involves transporting genetic materials like DNA, mRNA, siRNA, miRNA, and antisense oligonucleotides to target cells for therapeutic purposes. These therapies aim to regulate gene expression or correct genetic mutations at the molecular level, making them particularly powerful for treating genetic disorders, cancers, and viral infections.Therapeutically, nucleic acid drugs are showing promise in personalized medicine, particularly in oncology, rare diseases, and central nervous system disorders. Regulatory approvals for products like patisiran and nusinersen (antisense oligonucleotide) mark significant milestones in the field. 

Key topics:

• mRNA and siRNA drug delivery platforms
• Lipid nanoparticles and polymeric carriers
• CRISPR-Cas9 delivery systems
• Stability, cellular uptake, and targeting strategies
• Therapeutic applications and regulatory pathways
• Challenges in clinical translation and commercialization

Why Should You Attend?

The 18th World Drug Delivery Summit is a must-attend event for professionals and researchers dedicated to advancing drug delivery technologies. Here’s why you should join:

• Stay Ahead of the Curve: Discover the latest breakthroughs in smart drug delivery systems and controlled-release innovations.
• Expert Insights: Gain knowledge from world-renowned scientists, industry leaders, and keynote speakers.
• Networking Opportunities: Connect with global experts, researchers, and decision-makers to build meaningful collaborations.
• Cutting-Edge Technologies: Explore emerging trends, including AI-driven delivery systems, nanotechnology, and stimuli-responsive materials.
• Interactive Sessions: Engage in workshops, panel discussions, and Q&A sessions to exchange ideas and address current challenges.
• Career Growth: Enhance your expertise and expand your professional network in the rapidly evolving field of drug delivery.
• Showcase Your Research: Present your findings to a global audience and gain valuable feedback from peers.
• Industry Exposure: Interact with leading pharmaceutical and biotech companies showcasing their latest innovations.
• Global Platform: Be part of a diverse community working to revolutionize drug delivery for better healthcare outcomes.

Who Can Attend?

The 18th World Drug Delivery Summit is designed for professionals, researchers, and industry leaders working in the field of drug delivery and related disciplines. Specific attendees include:

• Pharmaceutical Scientists involved in drug formulation, delivery mechanisms, and controlled-release technologies.
• Biotechnology Experts developing biologics, biosimilars, and nanotechnology-based delivery systems.
• Clinical Pharmacologists researching pharmacokinetics and pharmacodynamics of advanced delivery methods.
• Material Scientists and Engineers working on smart polymers, nanomaterials, and biodegradable carriers for drug delivery.
• Medical Practitioners and Healthcare Professionals exploring novel delivery solutions to enhance patient care.
• Regulatory Affairs Specialists ensuring compliance, approval, and quality assurance for innovative drug delivery systems.
• Academicians and Researchers from universities and institutions contributing to advancements in the field.
• Industry Leaders and R&D Heads from pharmaceutical and biotechnology companies driving innovation.
• Biomedical Engineers developing devices for precision and non-invasive drug administration.
• Technology Developers specializing in wearable, implantable, and AI-driven drug delivery devices.

This conference provides a global platform for professionals dedicated to revolutionizing drug delivery systems and improving therapeutic outcomes.

Market Analysis

The global drug delivery systems market is projected to grow significantly from $200 billion in 2025 to $350 billion by 2030, driven by advancements in technology, the rising prevalence of chronic diseases, and increased demand for precision medicine. This growth, at a CAGR of 8-10%, is fueled by several key factors: the rising demand for biologics and targeted therapies, innovations in nanotechnology and AI-driven drug delivery systems, and the aging population requiring patient-friendly and controlled-release drug systems. Additionally, increased investment in research and development by pharmaceutical companies and governments is accelerating the development of next-generation delivery technologies. While North America remains the largest market, the Asia-Pacific region is expected to witness the fastest growth, owing to expanding healthcare infrastructure and improving drug accessibility. The graph above visually represents this strong upward trajectory, illustrating the market's expansion over the next five years. ?

Global associations and Societies

1. American Association of Pharmaceutical Scientists (AAPS)
2. International Society for Drug Delivery Systems (ISDDS)
3. European Society for the Study of Drug Delivery (ESSDD)
4. Controlled Release Society (CRS)
5. International Pharmaceutical Federation (FIP)
6. American Society for Nanomedicine (ASNM)
7. Society for Biomaterials (SFB)
8. British Pharmaceutical Society (BPS)
9. International Society for the Advancement of Material and Technology for Drug Delivery Systems (ISAMT)
10. Asian Association of Pharmaceutical Sciences (AAPS-Asia)

Past Conference Report

Drug Delivery 2024

The 17th World Drug Delivery Summit, scheduled for December 05-06, 2024, in Dubai, UAE, offers a premier platform for global experts in drug delivery to converge and exchange insights at the forefront of pharmaceutical sciences. With a focus on showcasing cutting-edge advancements in drug delivery technologies, the conference promises to unveil innovative approaches to enhance therapeutic efficacy and patient outcomes. Attendees can anticipate a diverse program encompassing topics ranging from fundamental research in drug delivery mechanisms to clinical applications and regulatory considerations. Keynote lectures, panel discussions, and interactive workshops will facilitate robust discussions and collaborations among academia, industry, and regulatory bodies. The strategic location of Dubai, a vibrant hub for innovation and commerce, further enhances the conference's appeal as a dynamic forum for networking and knowledge exchange.